The most important thing now is waiting for the CMS reimbursement amount imo, the amount is key. Needs to be high enough to actually support scaling. If they take on the pricing recommendation that's phenomenal news. If the price comes in too low it makes it really hard for them to roll the test out commercially, even if the clinical value is there. Hopeful and somewhat expecting it will remain around 390 even though the test is cheaper to produce due to the fact its clinical utility hasn't changed and the potential savings to the US system.
Ann: AMA grants reimbursement code for Next-Gen PromarkerD test, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $62.19M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.0¢ | $53.71K | 143.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 491 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 39195 | 2 |
View Market Depth
| Last trade - 15.55pm 07/08/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |